Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has successfully secured a $110 million Series E financing led by a private equity fund of Value Partners Group (HKG:0806), one of Asia's largest independent asset management firms, with strong participation from industry- and technology-focused new investors, as well as continued support from global existing backers.

The funds raised in this round will be directed to advance Insilico's innovative drug pipeline and AI platform developments. On one side, resources will focus on refining AI models and algorithms, alongside updates and expansions to its state-of-the-art automatic lab to further automate and streamline R&D processes. On the other side, Insilico will focus on advancing the clinical validation of its flagship candidate for idiopathic pulmonary fibrosis treatment and accelerating the exploration of other independently developed and co-developed drug pipelines, driving impactful innovations in healthcare.

"We are excited to partner with Insilico Medicine in its mission to transform drug discovery with AI and automation. With a proven track record and a leadership position in AI-driven drug development, Insilico is at the forefront of transforming the industry. We believe that Insilico's advancements will not only accelerate the development of life-saving therapies but also redefine the future of biopharmaceutical R&D. This partnership also marks a significant milestone for Value Partners' private equity strategy and our vision of investing in disruptive innovations that have the potential to reshape industries," said Dr. Chuen Yan Leung, Partner (Healthcare Investments).

"We are thrilled to announce our $110 million Series E financing—a key milestone that reflects our unwavering commitment to transforming healthcare and the strong confidence of our investors. This round, led by Value Partners and anchored by industry-focused investors, was heavily oversubscribed, drawing exceptional interest from prominent investors," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "The funds raised will accelerate the advancement of our drug pipeline and AI platform, further solidifying Insilico's leadership in this rapidly evolving sector. We remain dedicated to our mission of extending productive longevity to people and are proud to be at the forefront of innovation in healthcare."

Since its previous financing round, Insilico has achieved substantial progress in both the development of AI platform and drug discovery pipeline and has showcased the ability of its proprietary AI-driven platform to significantly reduce costs and enhance efficiency in the early stages of drug discovery. As its announced key benchmarks for internal preclinical candidate (PCC) programs show: By integrating advanced AI and automation technologies, Insilico has reduced the average time to PCC nomination to just 12-18 months compared to traditional drug discovery methods (typically require 2.5-4 years) , while enabling the synthesis and testing of only 60-200 molecules per program.

Pharma.AI, the proprietary platform developed by Insilico, undergoes major updates twice a year to maintain its technological edge. Built around generative AI and continuously integrating cutting-edge technologies, Pharma.AI provides a comprehensive solution spanning biology, generative chemistry, clinical medicine, and scientific research. As the technology evolves, Insilico has further enhanced Pharma.AI by introducing innovative engines powered by large language models (LLMs), including Nach01, a multimodal foundation model for natural and chemical languages, and Dora, a multi-agent generative research assistant. Recently, Insilico deployed the first bipedal humanoid AI Scientist within Life Star1, its fully robotic lab connected to Pharma.AI, designed to further optimize and automate research workflows.

To date, Insilico has rapidly built a wholly-owned drug discovery portfolio of 30 assets driven by its advanced Pharma.AI platform, with 10 of these assets receiving IND clearance. Among them, the most advanced candidate, Rentosertib (formerly known as ISM001-055), developed for treating idiopathic pulmonary fibrosis (IPF), has progressed through multiple clinical studies with encouraging results. In a completed Phase IIa clinical trial, Rentosertib demonstrated favorable safety and tolerability across all dose levels, along with dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.

In addition, Insilico has established a sustainable revenue stream through its business model centered on out-licensing deals for its pipelines. The company has secured four pipeline out-licensing agreements with Fosun Pharma, Exelixis, and Menarini, collectively valued at over $2.1 billion. Concurrently, Insilico has initiated multiple drug discovery and development collaborations with industry partners, including Sanofi, Saudi Aramco, Therasid Bioscience and others, with the collected value of over $1.4 billion. Many of these partnerships have reached milestones, resulting in milestone payments to Insilico, further contributing to the company's growing financial performance.

With the successful completion of its Series E financing, Insilico will further accelerate the advancement of AI-powered biopharmaceutical research and development, strengthen collaboration across the industry value chain, and drive the application of its cutting-edge AI platform in diverse scenarios within the life sciences sector through flagship use cases.